Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription.
Dupixent (dupilumab) is a brand-name subcutaneous injection that’s prescribed for atopic dermatitis, asthma, and more. It works to treat those conditions by blocking proteins that cause ...
In addition, Dupixent is approved to treat the following: corticosteroid-dependent asthma in children ages 6 years and older CRwNP in children ages 12 years and older atopic dermatitis (eczema ...
Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD: Paris Saturday, March 29, 2025, 09:00 Hrs [IST] The Ministry of Health, Labour an ...
In addition to COPD, Dupixent is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis and chronic spontaneous ...
4d
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...
Dupixent (dupilumab) is a prescription drug that works to treat certain inflammatory conditions, such as atopic dermatitis, by reducing inflammation signals in your immune system. Your response to ...
In addition to COPD, Dupixent is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis and chronic ...
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
In addition to COPD, Dupixent is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis, and chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback